Barclays’s MAIA Biotechnology MAIA Stock Holding History

Barclays’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.98K	Buy	+4,152	New	+$5.51K	﹤0.01%	4758

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's MAIA Position: Q2 2026 in Review

Barclays opened a new position in MAIA Biotechnology (MAIA) in Q2 2026: 4,152 shares worth $5.98K. The stake represents ﹤0.01% of the portfolio and ranks #4758 among its holdings.

36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

Barclays held 4,152 shares of MAIA Biotechnology worth $5.98K as of Q2 2026.
MAIA Biotechnology was a new Barclays position in Q2 2026.
MAIA Biotechnology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4758 holding.
36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.